Blood Journal
Leading the way in experimental and clinical research in hematology

Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-1472.

On page 1472 in the 16 August 2012 issue, there is an error in the reported patients treated with brentuximab vedotin. In the last sentence of “Results and discussion,” “in HL patients” should have read, “in 1 HL and 1 ALCL patient.” The sentence reads, “With respect to its application as first line therapy, 2 cases of progressive multifocal leukoencephalopathy have been reported in HL patients treated with brentuximab vedotin.” It should have read, “With respect to its application as first line therapy, 2 cases of progressive multifocal leukoencephalopathy have been reported in 1 HL and 1 ALCL patient treated with brentuximab vedotin.”